Compare Stocks

→ Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKLI Akili	$0.25 +3.8%	$0.28	$0.19 ▼ $1.67	$19.49M	1.99	1.93 million shs	147,767 shs
HSAQ Health Sciences Acquisitions Co. 2	$4.52 +0.4%	$5.56	$9.41 ▼ $13.80	$50.68M	0.09	205,918 shs	29,371 shs
NYXH Nyxoah	$10.61 +1.2%	$13.55	$4.00 ▼ $20.00	N/A	1.5	56,139 shs	17,967 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKLI Akili	+4.32%	+6.32%	-12.04%	-14.64%	-79.22%
HSAQ Health Sciences Acquisitions Co. 2	-2.59%	-3.00%	-14.07%	-51.97%	-67.69%
NYXH Nyxoah	-1.13%	+12.69%	-28.80%	+53.89%	+20.32%

Pentagon contract could send this $2 AI stock soaring (Ad)

Whenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...

Get all the info here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKLI Akili	2.9759 of 5 stars	3.5	5.0	0.0	0.0	1.1	1.7	1.3
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NYXH Nyxoah	2.4645 of 5 stars	4.4	4.0	0.0	0.0	0.0	0.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKLI Akili	3.00	Buy	$4.00	1,512.90% Upside
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A
NYXH Nyxoah	2.83	Moderate Buy	$20.60	94.16% Upside

Current Analyst Ratings

Latest AKLI, NYXH, and HSAQ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/20/2024	NYXH Nyxoah	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $22.00
3/20/2024	NYXH Nyxoah	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
3/14/2024	NYXH Nyxoah	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$17.00 ➝ $20.00
3/6/2024	NYXH Nyxoah	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
3/6/2024	NYXH Nyxoah	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$15.00 ➝ $20.00
3/5/2024	NYXH Nyxoah	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $20.00
2/28/2024	NYXH Nyxoah	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $18.00
2/9/2024	NYXH Nyxoah	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
2/1/2024	NYXH Nyxoah	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $15.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKLI Akili	$1.68M	11.60	N/A	N/A	$0.75 per share	0.33
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	($0.62) per share	N/A
NYXH Nyxoah	$4.70M	N/A	N/A	N/A	$5.08 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKLI Akili	-$59.49M	-$0.76	N/A	N/A	N/A	-3,545.47%	-76.34%	-56.48%	5/10/2024 (Estimated)
HSAQ Health Sciences Acquisitions Co. 2	-$380K	N/A	0.00	∞	N/A	N/A	N/A	-2.38%	N/A
NYXH Nyxoah	-$46.77M	-$1.68	N/A	N/A	N/A	-993.28%	-38.58%	-31.24%	5/21/2024 (Estimated)

Latest AKLI, NYXH, and HSAQ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/5/2024	Q4 2023	NYXH Nyxoah	-$0.41	-$0.41	N/A	-$0.41	$2.01 million	$1.96 million
2/29/2024	Q4 2023	AKLI Akili	-$0.26	-$0.14	+$0.12	-$0.14	$1.07 million	$0.75 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKLI Akili	N/A	N/A	N/A	N/A	N/A
HSAQ Health Sciences Acquisitions Co. 2	N/A	N/A	N/A	N/A	N/A
NYXH Nyxoah	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKLI Akili	0.09	6.02	6.02
HSAQ Health Sciences Acquisitions Co. 2	N/A	0.17	0.61
NYXH Nyxoah	0.12	4.73	4.50

Ownership

Institutional Ownership

Company	Institutional Ownership
AKLI Akili	53.12%
HSAQ Health Sciences Acquisitions Co. 2	89.71%
NYXH Nyxoah	N/A

Insider Ownership

Company	Insider Ownership
AKLI Akili	10.10%
HSAQ Health Sciences Acquisitions Co. 2	21.90%
NYXH Nyxoah	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AKLI Akili	68	78.60 million	70.66 million	Optionable
HSAQ Health Sciences Acquisitions Co. 2	4	11.21 million	8.76 million	Not Optionable
NYXH Nyxoah	137	N/A	N/A	Not Optionable

AKLI, NYXH, and HSAQ Headlines

Source	Headline
	Nyxoah Appoints Maurits Boon As Chief Medical Officer markets.businessinsider.com - April 11 at 10:01 PM
	Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer globenewswire.com - April 11 at 4:30 PM
	Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket benzinga.com - April 11 at 7:00 AM
	Information on the total number of voting rights and shares finance.yahoo.com - March 29 at 9:02 PM
	Buy Rating Affirmed for Nyxoah’s Genio System Amid Strategic Partnerships and Market Capture Potential markets.businessinsider.com - March 26 at 1:26 AM
	Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation globenewswire.com - March 25 at 2:05 AM
	Buy Rating Affirmed for Nyxoah Amid Promising DREAM Study Results and Market Growth Projections markets.businessinsider.com - March 20 at 4:13 PM
	Nyxoah says Genio pivotal study meets primary endpoints msn.com - March 19 at 9:57 PM
	Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints globenewswire.com - March 19 at 4:05 PM
	Nyxoah S.A. (NYXH) Q4 2023 Earnings Call Transcript seekingalpha.com - March 7 at 8:16 PM
	Nyxoah S.A. (NASDAQ:NYXH) Q4 2023 Earnings Call Transcript finance.yahoo.com - March 7 at 10:16 AM
	Buy Rating Affirmed for Nyxoah Amid Record Genio Sales and Strong Growth Prospects markets.businessinsider.com - March 6 at 4:41 PM
	NYXH Stock Earnings: Nyxoah Misses EPS, Beats Revenue for Q4 2023 investorplace.com - March 5 at 10:33 PM
	Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates zacks.com - March 5 at 7:01 PM
	Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating Results globenewswire.com - March 5 at 4:05 PM
	Preview: Nyxoah's Earnings benzinga.com - March 4 at 4:05 PM
	Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference globenewswire.com - February 29 at 4:30 PM
	Butterfly Network, ThermoGenesis among healthcare movers msn.com - February 26 at 10:58 AM
	Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024 finance.yahoo.com - February 15 at 7:18 PM
	Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024 globenewswire.com - February 15 at 4:30 PM
	Nyxoah SA Ordinary Shares NYXH morningstar.com - February 9 at 11:26 PM
	Nyxoah Announces 2024 Strategic Priorities finance.yahoo.com - January 17 at 4:17 PM
	Nyxoah expects to almost double revenue in 4Q23 msn.com - January 10 at 9:28 AM
	Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023 finance.yahoo.com - January 9 at 7:12 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akili

NASDAQ:AKLI

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

Health Sciences Acquisitions Co. 2

NASDAQ:HSAQ

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

Nyxoah

NASDAQ:NYXH

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial